INmune Bio, Inc.
NASDAQ:INMBBiotechnology
+$0.15 today
- Market cap
- $50.25M
- Beta
- 0.98
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.56
Volume 0.09M
Average 0.68M
INMB Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
INmune Bio, Inc.NASDAQ: INMB
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$19.85M, compared with -$18.99M a year earlier.
Context
- Net debt amounted to 76.9% of total assets at the end of Q1 FY2026, up 26.6 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -4.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (23.72M) USD
- Year-over-year change
- -15.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.72M) | -15.5% |
| FY2024 | 2024-12-31 | (20.54M) | +19.2% |
| FY2023 | 2023-12-31 | (25.41M) | +31.0% |
| FY2022 | 2022-12-31 | (36.84M) | +38.2% |
| FY2021 | 2021-12-31 | (59.58M) | — |
Net Debt vs competitors
How INMB compares with its peers on the latest reported figures
- INMB's Mar 2026 net debt of -$19.85M is the 2nd highest of the 4 companies compared; the peer median is -$139.66M.
- Its year-over-year change of -4.5% is the 2nd highest of 4, against a peer median of -100.3%.
- Net debt amounts to 76.9% of total assets for INMB, versus a peer median of 51.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$5.8M | +72.4% | — | 23.5% | |
| Mar 2026 | -$19.85M | -4.5% | — | 76.9% | |
| Mar 2026 | -$139.66M | -469.6% | — | 51.7% | |
OKUROnKure Therapeutics, Inc. | Mar 2026 | -$191.7M | -100.3% | — | 96.5% |
| Peer median (excluding INMB) | -$139.66M | -100.3% | — | 51.7% | |
Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74.81M | 52.15M | 35.85M | 20.92M | 24.75M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.5M | 8.46M | 2.44M | 1.41M | 4.54M |
| Inventory | (5.5M) | 34K | 0 | 0 | 0 |
| Other Current Assets | 5.5M | (34K) | 1.51M | 331K | 595K |
| Total Current Assets | 82.61M | 64.68M | 39.94M | 22.66M | 29.89M |
| Property, Plant & Equipment (Net) | 726K | 507K | 414K | 307K | 914K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 16.51M | 16.51M | 16.51M | 16.51M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 99K | 99K | 131K | 79K | 1.55M |
| Total Non-current Assets | 17.34M | 17.12M | 17.06M | 16.9M | 2.46M |
| Total Assets | 99.95M | 81.8M | 57M | 39.56M | 32.35M |
| Account Payables | 3.8M | 5.21M | 7.9M | 6.56M | 7.79M |
| Short-term Debt | 72K | 5M | 9.92M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 474K | 616K | 0 | 0 | 0 |
| Other Current Liabilities | (62K) | 9K | 524K | 517K | 0 |
| Total Current Liabilities | 4.36M | 10.92M | 18.47M | 7.22M | 8.42M |
| Long-term Debt | 14.46M | 9.7M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 199K | 550K | 0 | 0 | 0 |
| Total Non-current Liabilities | 15.36M | 10.77M | 397K | 244K | 411K |
| Total Liabilities | 19.72M | 21.69M | 18.86M | 7.47M | 8.83M |
| Common Stock | 18K | 18K | 817K | 22K | 27K |
| Retained Earnings | (63.72M) | (91.01M) | (121.02M) | (163.1M) | (209.04M) |
| Accumulated OCI | 1K | (699K) | (799K) | (575K) | (737K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 80.23M | 60.1M | 38.14M | 32.1M | 23.52M |
| Total Debt | 15.23M | 15.31M | 10.44M | 384K | 1.03M |
| Net Debt | (59.58M) | (36.84M) | (25.41M) | (20.54M) | (23.72M) |
INmune Bio, Inc.
NASDAQ:INMB
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.